Answers are grounded in this paper and cite their sources.
Phase-2 clinical trial shows surgical microwave ablation combined with durvalumab and tremelimumab improves progression-free survival in patients with pancreatic cancer, indicating potential for immun
These findings suggest that CD8-Temra cells may serve as potential biomarkers and therapeutic targets for immunotherapy efficacy in pancreatic ductal adenocarcinoma, pending validation in larger cohorts. We hypothesize that local tumor ablation may enhance tumor immunogenicity and systemic anti-tumor responses, supporting their integration into future treatment strategies. Future studies with larger cohorts are needed to validate these findings and optimize treatment protocols for wider clinical applicability.
No takes yet. Share an insight, caveat, or question.
Topal et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: